DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for bladder diverticulum — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBladder diverticulum maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for bladder diverticulum is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1968 review of 285 male patients with bladder diverticulum at the Mayo Clinic found that 19 patients (7 per cent) had malignant changes within the diverticulum. In 25 of the 31 patients who had elective diverticulectomy for non-malignant complications, the specimen showed evidence of premalignant changes. Based on that finding and a critical appraisal of mortality and morbidity, the authors recommended prophylactic excision of bladder diverticula as the therapy of choice.
A 1989 study of 13 patients who underwent transurethral diverticulectomy reported that follow-up cystograms six months after surgery showed the diverticulum had shrunk in all cases and had totally disappeared in 11 (85 per cent). The authors described the procedure as simple, effective, and safe, taking only a short time and easily combined with transurethral operations for lower urinary tract obstructions.
A 2025 case report described a two-week-old male neonate with acute urinary retention due to a large congenital bladder diverticulum. His retention was initially managed with clean intermittent catheterisation (CIC), and he underwent successful surgical excision of the diverticulum at seven months of age. The authors suggested that initial management with CIC may obviate the need for immediate surgery in neonates and young infants with congenital bladder diverticula presenting with acute urinary retention.
What is still missing are prospective controlled trials comparing different surgical approaches (open, transurethral, laparoscopic) and non-surgical management, particularly in paediatric and asymptomatic adult populations. No randomised data exist on the natural history of untreated small diverticula, and the optimal timing of intervention to prevent malignant transformation remains unknown. Patient stratification by diverticulum size, location, and presence of obstruction is not yet supported by evidence from comparative studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Urology · 1968 · 39 citations
BLADDER DIVERTICULUM IN THE MALE
AbstractSUMMARY A review of the clinical features, complications, and treatment of 285 maie patients with bladder diverticulum seen at the Mayo Clinic during a 10‐year period is presented. In 19 patients (7 per cent.), malignant changes within the diverticulum had occurred. In 25 of the 31 patients in whom elective diverticulectomy was done for non‐malignant complications, the specimen showed evidence of premalignant changes. Based on these findings, together with a critical appraisal of the mortality and morbidity of elective diverticulectomy in our own experience and in reported series, prophylactic excision of bladder diverticula is recommended as the therapy of choice.
The Japanese Journal of Urology · 1989 · 2 citations · open access
TRANSURETHRAL TREATMENT OF BLADDER DIVERTICULUM
Abstract13 patients with bladder diverticula underwent transurethral diverticulectomy. Follow-up cystograms were obtained six months after surgery. The diverticulum had shrunk in all cases and had totally disappeared in 11 (85%). Transurethral diverticulectomy is a simple, effective, and safe procedure. It takes only a short time and can easily be combined with transurethral operations for obstructions of the lower urinary tract.
Congenital Bladder Diverticulum Presenting as Urinary Retention in a Neonate: A Case Report
AbstractCongenital bladder diverticulum is a rare cause of acute urinary retention in infants and children, often requiring surgical repair. Given technical complexities and anesthetic risks associated with neonatal surgery, neonates presenting with urinary retention are typically managed using a staged approach involving an immediate vesicostomy followed by delayed surgical repair. We present the case of a two-week-old male neonate with acute urinary retention due to a large congenital bladder diverticulum. His urinary retention was initially managed with clean intermittent catheterization (CIC). He ultimately underwent successful surgical excision of the diverticulum at seven months of age. Initial management with CIC may obviate the need for immediate surgery in neonates and young infants with congenital bladder diverticula presenting with acute urinary retention.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
